Karen Rabenau1, Erin Hofstatter2. 1. Yale University School of Medicine/Yale Cancer Center, New Haven, CT. 2. Yale University School of Medicine/Yale Cancer Center, New Haven, CT. Electronic address: erin.hofstatter@yale.edu.
Abstract
PURPOSE: As a result of improved understanding of DNA repair mechanisms, poly(ADP-ribose) polymerase inhibitors (PARPi) are increasingly recognized to play an important therapeutic role in the treatment of cancer. The aim of this article is to provide a review of PARPi function in DNA damage repair and synthetic lethality and to demonstrate how these mechanisms can be exploited to provide new PARPi-based therapies to patients with solid tumors. METHODS: Literature from a range of sources, including PubMed and MEDLINE, were searched to identify recent reports regarding DNA damage repair and PARPi. FINDINGS: DNA damage repair is central to cellular viability. The family of poly(ADP-ribose) polymerase proteins play multiple intracellular roles in DNA repair, but function primarily in the resolution of repair of single-strand DNA breaks. Insights through the discovery of germline BRCA1/2 mutations led to the understanding of synthetic lethality and the potential therapeutic role of PARPi in the treatment of cancer. Further understanding of DNA damage repair and the concept of BRCA-like tumors have catalyzed PARPi clinical investigation in multiple oncologic settings. IMPLICATIONS: PARPi hold great promise in the treatment of solid tumors, both as monotherapy and in combination with other cancer therapeutics. Multiple PARPi clinical trials are currently underway. Further understanding of aberrant DNA repair mechanisms in the germline and in the tumor genome will allow clinicians and researchers to apply PARPi most strategically in the era of personalized medicine.
PURPOSE: As a result of improved understanding of DNA repair mechanisms, poly(ADP-ribose) polymerase inhibitors (PARPi) are increasingly recognized to play an important therapeutic role in the treatment of cancer. The aim of this article is to provide a review of PARPi function in DNA damage repair and synthetic lethality and to demonstrate how these mechanisms can be exploited to provide new PARPi-based therapies to patients with solid tumors. METHODS: Literature from a range of sources, including PubMed and MEDLINE, were searched to identify recent reports regarding DNA damage repair and PARPi. FINDINGS: DNA damage repair is central to cellular viability. The family of poly(ADP-ribose) polymerase proteins play multiple intracellular roles in DNA repair, but function primarily in the resolution of repair of single-strand DNA breaks. Insights through the discovery of germline BRCA1/2 mutations led to the understanding of synthetic lethality and the potential therapeutic role of PARPi in the treatment of cancer. Further understanding of DNA damage repair and the concept of BRCA-like tumors have catalyzed PARPi clinical investigation in multiple oncologic settings. IMPLICATIONS: PARPi hold great promise in the treatment of solid tumors, both as monotherapy and in combination with other cancer therapeutics. Multiple PARPi clinical trials are currently underway. Further understanding of aberrant DNA repair mechanisms in the germline and in the tumor genome will allow clinicians and researchers to apply PARPi most strategically in the era of personalized medicine.
Authors: Xiaofei Chen; Jade Mims; Xiumei Huang; Naveen Singh; Edward Motea; Sarah M Planchon; Muhammad Beg; Allen W Tsang; Mercedes Porosnicu; Melissa L Kemp; David A Boothman; Cristina M Furdui Journal: Antioxid Redox Signal Date: 2017-12-20 Impact factor: 8.401
Authors: Asha Sinha; Ali Saleh; Raelene Endersby; Shek H Yuan; Chirayu R Chokshi; Kevin R Brown; Bozena Kuzio; Tiina Kauppinen; Sheila K Singh; Suzanne J Baker; Peter J McKinnon; Sachin Katyal Journal: Cancers (Basel) Date: 2020-10-29 Impact factor: 6.575
Authors: Song Mu; Daniel Palmer; Richard Fitzgerald; Claudia Andreu-Vieyra; Heather Zhang; Zhiyu Tang; Dan Su; Srikumar Sahasranaman Journal: Clin Pharmacol Drug Dev Date: 2021-04-19